Sustainability officer

PD Dr. med. Simona Schlereth

Dr. med. Simona Schlereth

Department of Ophthalmology
University Hospital Cologne
Kerpener Str. 62, 50931 Cologne, Germany
+49 221 478 98896


Project leader

Scientific career

Since 2022 Senior physician, University Hospital of Cologne, Department of Ophthalmology

Dec. 2016 Specialist in Ophthalmology (“Deutscher Facharzt für Augenheilkunde”), since 2018 „Funktionsoberärztin“ at the University Hospital of Cologne, Department of Ophthalmology

May 2016 Fellow of the European Board of Ophthalmology (FEBO)

2011- 2016 Specialist training at the University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Ophthalmology

Feb-Dec. 2010 Research stay at the Schepens Eye Research Institute Boston, Harvard Medical School in the laboratory of Prof. Dana, Boston, USA

Prizes and honors

2022 Research award from the “Verein Rheinisch Westfälischer Augenärzte“

2016 Research award from the „ Eye Foundation of the German

2016 Research rotational position by FOR2240

2014 Gabriele Lederle foundation

2013 Research funding by Cologne Gerok program

2013 Travel Grant der Women in Eye & Vision Research to the ARVO- conference in Seattle, USA

2012 Henning Zügel Prize for basic research in Ophthalmology

Selected publications

  1. Schlereth SL and Schrittenlocher S, Siebelmann S, Hayashi T, Matthaei M, Bachmann B, Cursiefen C.: Long-term outcome of descemet membrane endothelial keratoplasty (DMEK) following failed penetrating keratoplasty. Acta Ophthalmol. 2020 Mar 20.
  2. Schlereth S, Lee HS, Khandelwal P, Saban DR: Blocking CCR7 at the ocular surface impairs the pathogenic contribution of dendritic cells in allergic conjunctivitis. Am J Pathol. 2012 Jun;180(6):2351-60.
  3. Smith RE, Reyes NJ, Khandelwal P, Schlereth SL; Lee HS, Masli S, Saban DR.: Secondary allergic T cell responses are regulated by dendritic cell-derived thrombospondin-1 in the setting of allergic eye disease. J. Leukoc Biol. 2016 Aug;100(2):371-80.
  4. Schlereth SL, Kremers S, Schrödl F, Cursiefen C, Heindl LM.: Characterization of Antigen-Presenting Macrophages and Dendritic Cells in the Healthy Human Sclera. Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4878-4885.
  5. Schlereth SL, Iden S, Mescher M, Ksander BR, Bosch JJ, Cursiefen C, Heindl LM.: A Novel Model of Metastatic Conjunctival Melanoma in Immune-Competent Mice. Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5965-73.
  6. Schlereth SL, Neuser B, Caramoy A, Grajewski RS, Koch KR, Schrödl F, Cursiefen C, Heindl LM: Enrichment of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1)-positive macrophages around blood vessels in the normal human sclera. Invest Ophthalmol Vis Sci. 2014 Feb 10;55(2):865-72.
  7. Schlereth SL and Lee HS, Park EY, Emami-Naeini P, Chauhan SK, Dana R: A novel pro-angiogenic function for interferon-γ-secreting natural killer cells. Invest Ophthalmol Vis Sci. 2014 May 2;55(5):2885-92.
  8. Schlereth SL, Neuser B, Herwig MC, Müller AM, Koch KR, Reitsamer HA, Schrödl F, Cursiefen C, Heindl LM: Absence of lymphatic vessels in the developing human sclera. Exp Eye Res. 2014 Aug;125:203-9.
  9. Schlereth SL, Hos D, Matthaei M., Hos D, Matthaei M, Hamrah P, Schmetterer L, O’Leary O, Ullmer C, Horstmann J, Bock F, Wacker K, Schröder H, Notara M, Haagdorens M, Nuijts RMMA, Dunker S, Dickman M, Fauser S, Scholl HPN, Wheeler-Schilling T, Cursiefen C.: New Technologies in Clinical Trials in Corneal Diseases and Limbal Stem Cell Defiency – Review from the European Vision Institute (EVI) Special Interest Focus Group Meeting. Ophthalmic Research. 2021; 64(2):145-167. Review
  10. Schlereth SL and Hos D, Bock F, Heindl LM, Cursiefen C: Antilymphangiogenic therapy to promote transplant survival and to reduce cancer metastasis: what can we learn from the eye? Semin Cell Dev Biol. 2014 Nov 20. pii: S1084-9521(14)00313-9. Review